Financhill
Sell
36

CVM Quote, Financials, Valuation and Earnings

Last price:
$5.57
Seasonality move :
13.82%
Day range:
$5.44 - $5.95
52-week range:
$1.98 - $20.41
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.04x
Volume:
58.4K
Avg. volume:
69.2K
1-year change:
-50.15%
Market cap:
$16.6M
Revenue:
--
EPS (TTM):
-$5.45

Analysts' Opinion

  • Consensus Rating
    CEL-SCI Corp. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $42.50, CEL-SCI Corp. has an estimated upside of 675.55% from its current price of $5.48.
  • Price Target Downside
    According to analysts, the lowest downside price target is $25.00 representing 100% downside risk from its current price of $5.48.

Fair Value

  • According to the consensus of 1 analyst, CEL-SCI Corp. has 675.55% upside to fair value with a price target of $42.50 per share.

CVM vs. S&P 500

  • Over the past 5 trading days, CEL-SCI Corp. has overperformed the S&P 500 by 4.76% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • CEL-SCI Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • CEL-SCI Corp. revenues have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter CEL-SCI Corp. reported revenues of --.

Earnings Growth

  • CEL-SCI Corp. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter CEL-SCI Corp. reported earnings per share of -$0.76.
Enterprise value:
15.1M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-0.88x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$3.9M
Return On Assets:
-103.31%
Net Income Margin (TTM):
--
Return On Equity:
-230.36%
Return On Invested Capital:
-117.93%
Operating Margin:
--
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Income Statement
Revenue -- -- -- -- --
Gross Profit -$4M -$4M -$3.9M -$991.6K -$960.8K
Operating Income -$31.5M -$26.4M -$24.8M -$6.1M -$6M
EBITDA -$27.5M -$22.4M -$20.9M -$5.1M -$5.1M
Diluted EPS -$0.73 -$3.28 -$5.45 -$2.87 -$0.76
Period Ending 2021-09-30 2022-09-30 2023-09-30 2024-09-30 2025-09-30
Balance Sheet
Current Assets $45.3M $25.4M $6.9M $6.1M $11.6M
Total Assets $75.9M $50.5M $30.5M $27M $28.2M
Current Liabilities $3.9M $4.7M $5.6M $4.6M $5.1M
Total Liabilities $19.3M $18.4M $17.3M $14.1M $12.2M
Total Equity $56.5M $32.2M $13.2M $12.9M $16M
Total Debt $15.9M $15.1M $13.4M $11.4M $9.2M
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Cash Flow Statement
Cash Flow Operations -$20.5M -$18.8M -$17.1M -$4.9M -$4.7M
Cash From Investing -$372.3K -$108.1K -$38.1K -$19.8K -$5.2K
Cash From Financing $4.7M $19.5M $23.4M $9.2M $13.8M
Free Cash Flow -$20.9M -$18.9M -$17.2M -$4.9M -$4.7M
CVM
Sector
Market Cap
$16.6M
$28.1M
Price % of 52-Week High
26.85%
51.87%
Dividend Yield
0%
0%
Shareholder Yield
-88.17%
-1.59%
1-Year Price Total Return
-50.15%
-17.31%
Beta (5-Year)
0.538
0.495
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $5.63
200-day SMA
Sell
Level $6.82
Bollinger Bands (100)
Sell
Level 6.17 - 9.99
Chaikin Money Flow
Sell
Level -30.5M
20-day SMA
Sell
Level $5.64
Relative Strength Index (RSI14)
Sell
Level 45.78
ADX Line
Sell
Level 26.33
Williams %R
Neutral
Level -37.7135
50-day SMA
Sell
Level $6.41
MACD (12, 26)
Sell
Level -0.26
25-day Aroon Oscillator
Sell
Level -24
On Balance Volume
Sell
Level -22.3M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (-28.0811)
Sell
CA Score (Annual)
Level (-4.418)
--
Beneish M-Score (Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (6.8531)
--
Piotroski F Score (Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)

Revenue Forecast

Earnings per Share Forecast

Company Profile

CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Stock Forecast FAQ

In the current month, CVM has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CVM average analyst price target in the past 3 months is $42.50.

  • Where Will CEL-SCI Corp. Stock Be In 1 Year?

    According to analysts, the consensus estimate is that CEL-SCI Corp. share price will rise to $42.50 per share over the next 12 months.

  • What Do Analysts Say About CEL-SCI Corp.?

    Analysts are divided on their view about CEL-SCI Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that CEL-SCI Corp. is a Sell and believe this share price will drop from its current level to $25.00.

  • What Is CEL-SCI Corp.'s Price Target?

    The price target for CEL-SCI Corp. over the next 1-year time period is forecast to be $42.50 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is CVM A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for CEL-SCI Corp. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.

  • How Can I Buy Shares Of CVM?

    You can purchase shares of CEL-SCI Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase CEL-SCI Corp. shares.

  • What Is The CEL-SCI Corp. Share Price Today?

    CEL-SCI Corp. was last trading at $5.57 per share. This represents the most recent stock quote for CEL-SCI Corp.. Yesterday, CEL-SCI Corp. closed at $5.48 per share.

  • How To Buy CEL-SCI Corp. Stock Online?

    In order to purchase CEL-SCI Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will The Magnificent 7 Stocks Go Up This Year?
Will The Magnificent 7 Stocks Go Up This Year?

2025 was another banner year for the Magnificent Seven stocks,…

Why Did Planet Labs Stock Rally So Much?
Why Did Planet Labs Stock Rally So Much?

Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…

Why Did Stan Druckenmiller Sell Broadcom Stock?
Why Did Stan Druckenmiller Sell Broadcom Stock?

In Q3, legendary macro investor Stan Druckenmiller sold his entire…

Stock Ideas

Buy
52
Is NVDA Stock a Buy?

Market Cap: $4.5T
P/E Ratio: 63x

Buy
65
Is GOOG Stock a Buy?

Market Cap: $4T
P/E Ratio: 41x

Buy
51
Is GOOGL Stock a Buy?

Market Cap: $4T
P/E Ratio: 41x

Alerts

Buy
100
ATGL alert for Jan 10

Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.

Buy
71
NAIL alert for Jan 10

Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.

Buy
54
LGIH alert for Jan 10

LGI Homes, Inc. [LGIH] is up 13.81% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock